LCM
SEEL

Lynwood Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Lynwood Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-313
Closed -$55.6K – 81
2023
Q4 		$55.6K Buy
+313
New +$154K 0.24% 28

Other funds holding SEEL

WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $381M AUM 21.36% 1-Year Est. Return

Lynwood Capital Management's SEEL Position: Q1 2024 in Review

Lynwood Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 313 shares — an estimated $55.6K sold.

Lynwood Capital Management first reported a position in SEEL in Q4 2023 and held it in 1 quarter. The position peaked at $55.6K in Q4 2023. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

  • Lynwood Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Lynwood Capital Management sold 313 Seelos Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $55.6K.
  • Lynwood Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Lynwood Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $55.6K in Q4 2023.
  • 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Lynwood Capital Management's 13F filing for Q1 2024, filed 10 May 2024.